$TNXP News

Tonix Pharma Presents Data From Analysis Of Phase 3 RELIEF And RESILIENT Studies Of TONMYA For Treatment Of Fibromyalgia In Adults, At IASP 2026 World Congress

Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026

Canaccord Genuity Initiates Coverage On Tonix Pharmaceuticals with Buy Rating, Announces Price Target of $18

Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain

Tonix Pharmaceuticals To Present Effects Of TONMYA On Fibromyalgia Symptoms And Physical Function At The World Congress On Pain, October 26-30

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026

Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic TONMYA On Oct 1; Paragraph IV Certification Challenges Four TONMYA Patents Listed In FDA Orange Book; Co Intends To Enforce TONMYA Intellectual Property Rights

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

Tonix Pharmaceuticals Announces Second Major Managed Medicare Agreement For TONMYA

Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26

Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference

Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline

Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript

Tonix Pharmaceuticals Holding Corp. 2026 Q2 - Results - Earnings Call Presentation

Tonix Delivers A Beat, But The Real Test Starts Now

Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ...

Tonix Pharmaceuticals Q2 Earnings Call Highlights

Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript